Aredia and Dermatitis exfoliative aggravated - a phase IV clinical study of FDA data
Dermatitis exfoliative aggravated is found among people who take Aredia, especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years.
The phase IV clinical study analyzes which people take Aredia and have Dermatitis exfoliative aggravated. It is created by eHealthMe based on reports of 15,205 people who have side effects when taking Aredia from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
15,205 people reported to have side effects when taking Aredia.
Among them, 23 people (0.15%) have Dermatitis exfoliative aggravated.
What is Aredia?
Aredia has active ingredients of pamidronate disodium. It is often used in breast cancer. eHealthMe is studying from 15,283 Aredia users for its effectiveness, alternative drugs and more.
What is Dermatitis exfoliative aggravated?
Dermatitis exfoliative aggravated (aggravated widespread scaling of the skin, often with itching (pruritus), skin redness (erythroderma), and hair loss) is found to be associated with 900 drugs and 273 conditions by eHealthMe.
Number of Aredia and Dermatitis exfoliative aggravated reports submitted per year:
Time on Aredia when people have Dermatitis exfoliative aggravated *:
- < 1 month: 0.0 %
- 1 - 6 months: 0.0 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 100 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Dermatitis exfoliative aggravated when taking Aredia *:
- female: 72.73 %
- male: 27.27 %
Age of people who have Dermatitis exfoliative aggravated when taking Aredia *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 4.55 %
- 50-59: 13.64 %
- 60+: 81.82 %
Common drugs people take besides Aredia *:
- Neupogen: 14 people, 60.87%
- Zometa: 13 people, 56.52%
- Fosamax: 12 people, 52.17%
- Provera: 12 people, 52.17%
- Rituxan: 12 people, 52.17%
- Melphalan Hydrochloride: 11 people, 47.83%
- Zofran: 11 people, 47.83%
- Premarin: 11 people, 47.83%
- Septra: 10 people, 43.48%
- Glutamine: 10 people, 43.48%
Common side effects people have besides Dermatitis exfoliative aggravated *:
- Anaemia (lack of blood): 15 people, 65.22%
- Rashes (redness): 14 people, 60.87%
- Weakness: 13 people, 56.52%
- Coronary Heart Disease (narrowing or blockage of the coronary arteries): 13 people, 56.52%
- Osteonecrosis Of Jaw (death of bone of jaw): 13 people, 56.52%
- Jaw Disorder (jaw disease): 13 people, 56.52%
- Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 13 people, 56.52%
- Itching: 13 people, 56.52%
- Atelectasis (partial or complete collapse of the lung): 13 people, 56.52%
- Pleural Effusion (water on the lungs): 13 people, 56.52%
Common conditions people have *:
- Immunodeficiency Disorders: 12 people, 52.17%
- Aseptic Necrosis (the death of bone tissue due to a lack of blood supply): 12 people, 52.17%
- Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 4.35%
- Pleural Disorder: 1 person, 4.35%
- Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 1 person, 4.35%
- Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 1 person, 4.35%
* Approximation only. Some reports may have incomplete information.
Do you take Aredia and have Dermatitis exfoliative aggravated?Check whether Dermatitis exfoliative aggravated is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Dermatitis exfoliative aggravated and when was it recovered:
Expand to all the drugs that have ingredients of pamidronate disodium:
Alternative drugs to, pros and cons of Aredia:
- Aredia (15,283 reports)
Common Aredia side effects:
- Pain: 5,860 reports
- Aseptic necrosis (the death of bone tissue due to a lack of blood supply): 5,034 reports
- Stress and anxiety: 4,837 reports
- Osteomyelitis (infection of bone): 3,477 reports
Browse all side effects of Aredia:a b c d e f g h i j k l m n o p q r s t u v w x y z
Dermatitis exfoliative aggravated treatments and more:
- Dermatitis exfoliative aggravated (4 reports)
COVID vaccines that are related to Dermatitis exfoliative aggravated:
- Dermatitis exfoliative aggravated in Moderna COVID Vaccine
- Dermatitis exfoliative aggravated in Pfizer BioNTech Covid Vaccine
- Dermatitis exfoliative aggravated in Johnson and Johnson Covid Vaccine
Common drugs associated with Dermatitis exfoliative aggravated:
- Renova: 646 reports
- Lopurin: 454 reports
- Allopurinol: 453 reports
- Furosemide: 346 reports
- Prednisone: 318 reports
- Aspirin: 318 reports
- Omeprazole: 285 reports
- Bactrim: 256 reports
- Methotrexate: 241 reports
- Plavix: 236 reports
All the drugs that are associated with Dermatitis exfoliative aggravated:
- Dermatitis exfoliative aggravated (900 drugs)
Common conditions associated with Dermatitis exfoliative aggravated:
- High blood pressure: 383 reports
- Psoriasis: 377 reports
- Epilepsy: 175 reports
- Preventive health care: 168 reports
- Pain: 153 reports
- Hiv infection: 141 reports
All the conditions that are associated with Dermatitis exfoliative aggravated:
- Dermatitis exfoliative aggravated (273 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on pamidronate disodium (the active ingredients of Aredia) and Aredia (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Allopurinol and Optic Nerve Sheath Haemorrhage - now
- Alprazolam and Abnormal Dreams - a second ago
- Allopurinol and Electrocardiogram Qt Shortened - 3 seconds ago
- Venlafaxine Hydrochloride and Ribavirin drug interaction - 7 seconds ago
- Carfilzomib and Bleeding Disorders - 8 seconds ago
- Allopurinol and Oral Mucosal Sloughing - 19 seconds ago
- Actifed and Metronidazole drug interaction - 19 seconds ago
- Allopurinol and Hypomagnesaemia - 20 seconds ago
- Ginger and Dry Mouth - 21 seconds ago
- Jakafi and Aleve drug interaction - 27 seconds ago